Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...
LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...
A cGMP-related CRL can delay approval despite substantial efficacy/safety evidence and often requires manufacturing remediation and reinspection rather than additional clinical trials. Phase III CARES ...
Extensive background and on-study uptake of TTR stabilizers likely diluted the observable marginal effect of a TTR-silencing agent, complicating attribution of benefit in the intent-to-treat primary ...
Approval was supported by IRAKLIA Phase III non-inferiority data comparing on-body injector subcutaneous isatuximab to weight-based IV, both combined with pomalidomide and dexamethasone in R/R myeloma ...
FDA’s July 2025 transparency initiative published 200+ redacted CRLs across drugs, biosimilars, and devices, offering granular insight into approvability deficiencies and review logic beyond ...
In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...
FDA cleared Ennumo as a Neulasta biosimilar for febrile neutropenia prophylaxis in non-myeloid malignancy patients receiving myelosuppressive chemotherapy, including pediatric populations from ...
The collaboration is positioned as a translational bridge for researchers and entrepreneurs, offering an end-to-end discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results